We are live on
!
Find out more
DCMIC
Decheng Capital Management III (Cayman) Portfolio holdings
AUM
$300M
1-Year Est. Return
15.74%
This Fund
S&P 500
This Quarter
Est. Return
-25.18%
1 Year Est. Return
+15.74%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$326M
AUM Growth
–
Cap. Flow
+$360M
Cap. Flow
% of AUM
110.41%
Top 10 Holdings %
Top 10 Hldgs %
82.72%
Holding
24
New
24
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HLTH
Cue Health Inc. Common Stock
HLTH
|
+$81.2M |
| 2 |
Illumina
ILMN
|
+$53.6M |
| 3 |
ALPN
Alpine Immune Sciences Inc
ALPN
|
+$40.7M |
| 4 |
Arcus Biosciences
RCUS
|
+$29.1M |
| 5 |
10x Genomics
TXG
|
+$26.6M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HLTH
1
DELISTED
Cue Health Inc. Common Stock
HLTH
| $57.9M | 17.75% |
+8,980,909
| New | +$81.2M |
|
|
2
Illumina
ILMN
$28.4B
| $53.9M | 16.52% |
+158,557
| New | +$53.6M |
|
|
ALPN
3
DELISTED
Alpine Immune Sciences Inc
ALPN
| $42.2M | 12.94% |
+4,708,288
| New | +$40.7M |
|
|
4
Arcus Biosciences
RCUS
$3.64B
| $27.5M | 8.41% |
+869,790
| New | +$29.1M |
|
|
5
10x Genomics
TXG
$6.61B
| $23.1M | 7.09% |
+303,984
| New | +$26.6M |
|
|
ALBO
6
DELISTED
Albireo Pharma Inc
ALBO
| $15.5M | 4.74% |
+518,342
| New | +$15.2M |
|
7
Equillium
EQ
$133M
| $14M | 4.29% |
+4,447,308
| New | +$16.3M |
|
8
Pacific Biosciences
PACB
$370M
| $13.3M | 4.08% |
+1,463,872
| New | +$16.9M |
|
9
Adicet Bio
ACET
$74.7M
| $11.6M | 3.55% |
+36,250
| New | +$8.34M |
|
10
BeyondSpring
BYSI
$35.8M
| $10.9M | 3.34% |
+4,958,142
| New | +$14.4M |
|
11
GeneDx Holdings
WGS
$2.3B
| $10.5M | 3.22% |
+103,604
| New | +$11.5M |
|
|
RXDX
12
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $9.44M | 2.89% |
+250,000
| New | +$9.88M |
|
|
WHWK
13
Whitehawk Therapeutics
WHWK
$271M
| $8.93M | 2.74% |
+526,329
| New | +$10.1M |
|
14
Aura Biosciences
AURA
$826M
| $4.62M | 1.42% |
+210,000
| New | +$4M |
|
|
CMPI
15
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
| $4.25M | 1.3% |
+1,333,254
| New | +$3.83M |
|
16
Owlet
OWLT
$160M
| $4M | 1.23% |
+64,171
| New | +$2.21M |
|
|
MRSN
17
DELISTED
Mersana Therapeutics
MRSN
| $3.61M | 1.11% |
+36,171
| New | +$4.23M |
|
18
SCYNEXIS
SCYX
$52M
| $2.17M | 0.67% |
+69,444
| New | +$2.66M |
|
|
TERN
19
DELISTED
Terns Pharmaceuticals
TERN
| $2.12M | 0.65% |
+714,285
| New | +$3.05M |
|
|
NBSE
20
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
| $1.88M | 0.58% |
+50,000
| New | +$1.73M |
|
21
Nautilus Biotechnolgy
NAUT
$115M
| $1.3M | 0.4% |
+300,000
| New | +$1.23M |
|
22
908 Devices
MASS
$364M
| $380K | 0.12% |
+20,000
| New | +$344K |
|
|
OMIC
23
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $126K | 0.04% |
+667
| New | +$154K |
|
Similar funds
IBT
3LCM
DT
SFG
TFA
AEPLI
CC
KBC
Decheng Capital Management III (Cayman)'s Q1 2022 Portfolio in Review
Q1 2022 is the first quarter with a 13F filing on record for Decheng Capital Management III (Cayman), which disclosed 24 positions worth $326M. Its ten largest holdings account for 83% of the portfolio.
Its largest position is Cue Health Inc. Common Stock: 8,980,909 shares worth $57.9M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets.
- Decheng Capital Management III (Cayman)'s largest Q1 2022 buy was Cue Health Inc. Common Stock: 8,980,909 shares worth $57.9M.
- Decheng Capital Management III (Cayman)'s ten largest holdings make up 83% of its $326M portfolio in Q1 2022.
- Decheng Capital Management III (Cayman) disclosed 24 positions in Q1 2022, its first 13F filing on record.
Based on Decheng Capital Management III (Cayman)'s 13F filing for Q1 2022, filed 10 May 2022.